Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results

被引：1

作者：

Sitbon, Olivier ^{[1
]}

Channick, Richard ^{[2
]}

Chin, Kelly ^{[3
]}

Frey, Aline ^{[4
]}

Galie, Nazzareno ^{[5
]}

Ghofrani, Hossein-Ardeschir ^{[6
]}

Hoeper, Marius M. ^{[7
,8
]}

Lang, Irene ^{[9
]}

Le Brun, Franck-Olivier ^{[4
]}

McLaughlin, Vallerie ^{[10
]}

Preiss, Ralph ^{[4
]}

Rubin, Lewis J. ^{[11
]}

Simonneau, Gerald ^{[1
]}

Tapson, Victor ^{[12
]}

Gaine, Sean ^{[13
]}

机构：

[1] Univ Paris Sud, Hop Univ Bicetre, Le Kremlin Bicetre, France

[2] Massachusetts Gen Hosp, Pulm & Crit Care, Boston, MA 02114 USA

[3] Univ Texas Southwestern Med Ctr Dallas, Pulm Hypertens Program, Dallas, TX 75390 USA

[4] Actel Pharmaceut Ltd, Clin Res, Allschwil, Switzerland

[5] Univ Bologna, Ist Malattie Apparato Cardiovasc, Bologna, Italy

[6] UGMLC, Giessen, Germany

[7] Hannover Med Sch, Dept Resp Med, Hannover, Germany

[8] German Ctr Lung Res, Hannover, Germany

[9] Med Univ Vienna, AKH, Dept Internal Med 2, Div Cardiol, Vienna, Austria

[10] Univ Michigan Hlth Syst, Div Cardiovasc Med, Ann Arbor, MI USA

[11] Univ Calif San Diego, Div Pulm & Crit Care Med, San Diego, CA 92103 USA

[12] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA

[13] Mater Misericordiae Univ Hosp, Natl Pulm Hypertens Unit, Dublin, Ireland

来源：

EUROPEAN RESPIRATORY JOURNAL | 2015年 / 46卷

关键词：

Pulmonary hypertension;

D O I：

10.1183/13993003.congress-2015.OA4995

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

OA4995

引用

页数：3

共 50 条

[31] Long-Term Outcomes With Ambrisentan Monotherapy in Pulmonary Arterial Hypertension
Blalock, Shannon E.
Matulevicius, Susan
Mitchell, Laura C.
Reimold, Sharon
Warner, John
Peshock, Ronald
Torres, Fernando
Chin, Kelly M.
JOURNAL OF CARDIAC FAILURE, 2010, 16 (02) : 121 - 127
[32] Long-term results of the DelIVery for Pulmonary Arterial Hypertension trial
Gomberg-Maitland, Mardi
Bourge, Robert C.
Shapiro, Shelley M.
Tarver, James H., III
Zwicke, Dianne L.
Feldman, Jeremy P.
Chakinala, Murali M.
Frantz, Robert P.
Torres, Fernando
Bag, Remzi
Murphy, Jeffrey A.
Lautenbach, Amy A.
Morris, Marty
Peterson, Leigh
Waxman, Aaron B.
PULMONARY CIRCULATION, 2019, 9 (04)
[33] Long-term outcomes with initial triple oral therapy in pulmonary arterial hypertension (PAH): Insights from TRITON
Sitbon, Olivier
Galie, Nazzareno
Doelberg, Martin
Gibbs, J. Simon R.
Hoeper, Marius M.
Stefani, Mylene
Mathai, Stephen C.
Mclaughlin, Vallerie
Perchenet, Loic
Simonneau, Gerald
Chin, Kelly
EUROPEAN RESPIRATORY JOURNAL, 2020, 56
[34] LONG-TERM OUTCOMES WITH INITIAL TRIPLE ORAL THERAPY IN PULMONARY ARTERIAL HYPERTENSION (PAH): INSIGHTS FROM TRITON
Howard, L.
Sitbon, O.
Galie, N.
Doelberg, M.
Gibbs, J. S. R.
Hoeper, M. M.
Stefani, M.
Mathai, S. C.
McLaughlin, Vv
Perchenet, L.
Simonneau, G.
Chin, K. M.
THORAX, 2021, 76 : A57 - A57
[35] Long-term outcomes and predictors of mortality in systemic lupus erythematosus (SLE) associated pulmonary arterial hypertension (PAH)
Li, M.
Wang, Q.
Zhao, J.
Zeng, X.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2015, 33 (03) : S48 - S48
[36] Clinical Characteristics and Treatment Patterns in Patients with Pulmonary Arterial Hypertension (PAH) Initiating Selexipag in the EXPOSURE Observational Study
Lange, T. J.
Escribano, P.
Biedermann, P.
Muller, A.
Sun, H.
Soderberg, S.
Gaine, S.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
[37] Clinical Characteristics and Treatment Patterns in Patients with Pulmonary Arterial Hypertension (PAH) Initiating Selexipag in the EXPOSURE Observational Study
Lange, T. J.
Escribano, P.
Biedermann, P.
Muller, A.
Sun, H.
Soderberg, S.
Gaine, S.
PNEUMOLOGIE, 2021, 75 : S22 - S22
[38] Persistence and Predictors of Persistency for Pulmonary Arterial Hypertension (PAH) Patients on Selexipag in Canada: A Retrospective Claims Database Study
Ibrahim, E.
Mielniczuk, L.
Provencher, S.
Swiston, J.
Weatherald, J.
Yip, C.
Zhang, C.
Murray, J.
Badin, M.
Golden, S.
Millson, B.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
[39] Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study
Preston, Ioana R.
Channick, Richard N.
Chin, Kelly
Di Scala, Lilla
Farber, Harrison W.
Gaine, Sean
Galie, Nazzareno
Ghofrani, Hossein-Ardeschir
Hoeper, Marius M.
Lang, Irene M.
McLaughlin, Vallerie V.
Preiss, Ralph
Simonneau, Gerald
Sitbon, Olivier
Tapson, Victor F.
Rubin, Lewis J.
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2018, 37 (03): : 401 - 408
[40] Impact of initial treatment strategy on long-term survival in pulmonary arterial hypertension (PAH)
Boucly, Athenais
Savale, Laurent
Weatherald, Jason
Montani, David
Jevnikar, Mitja
Jais, Xavier
Simonneau, Gerald
Humbert, Marc
Sitbon, Olivier
EUROPEAN RESPIRATORY JOURNAL, 2018, 52

← 1 2 3 4 5 →